Long-term Efficacy of Liraglutide in the Treatment of Patients with Type 2 Diabetes

Nambu Takuo, Murakami Takaaki, Matsuda Yuki, Matsuo Koji, Yonemitsu Shin, Muro Seiji, Oki Shogo

doi:10.11213/tonyobyo.57.153

Bibliographic Information

Other Title

GLP-1受容体作動薬「リラグルチド」の2型糖尿病患者に対する1年間使用成績
診断・治療(食事・運動・薬物) GLP-1受容体作動薬「リラグルチド」の2型糖尿病患者に対する1年間使用成績
シンダン・チリョウ(ショクジ・ウンドウ・ヤクブツ) GLP-1 ジュヨウタイサドウヤク「リラグルチド」ノ 2ガタトウニョウビョウカンジャニタイスル 1ネンカンシヨウセイセキ

Search this article

Description

The long-term efficacy of liraglutide, a glucagon-like peptide-1 receptor agonist, was evaluated in type 2 diabetes patients (n=100) who had received the drug for 12 months. The mean HbA1c level improved (8.4±0.2 % to 7.4±0.1 %) and the mean body weight decreased (71.8±1.8 kg to 68.1±1.7 kg) during the 12-month observation period. The patients were divided into two groups according to the HbA1c level at 12 months: Group A (HbA1c<7 %) and Group B (HbA1c≥7 %). Compared with the patients in Group A, those in Group B exhibited higher initial HbA1c levels, an increased incidence of diabetic nephropathy and a higher prevalence of previous exposure to insulin-sensitizing agents. Furthermore, the mean body weight in Group B decreased with a transient increment, whereas that in Group A decreased consistently. Liraglutide is effective for the long-term treatment of patients with type 2 diabetes; however, the efficacy of this drug in achieving glycemic control varies among individuals based on the initial HbA1c level, diabetic microvascular complications, previous use of oral antidiabetic agents and decreases in body weight.

Journal

Journal of the Japan Diabetes Society

Journal of the Japan Diabetes Society 57 (3), 153-161, 2014

THE JAPAN DIABETES SOCIETY

Keywords

Details 詳細情報について

Export

Report a problem